AU2007229554A1 - Anti-IGF-1R human monoclonal antibody formulation - Google Patents

Anti-IGF-1R human monoclonal antibody formulation Download PDF

Info

Publication number: AU2007229554A1
Authority: AU; Australia
Prior art keywords: igf; mlhumab; histidine; polysorbate; nac1
Prior art date: 2006-03-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2007229554A

Other languages

English (en)

Inventor

Adelbert Grossmann

Hanns-Christian Mahler

Astrid Pappenberger

Oliver Boris Stauch

Jan Olaf Stracke

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

F Hoffmann La Roche AG

Original Assignee

F Hoffmann La Roche AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-28

Filing date

2007-03-19

Publication date

2007-10-04

2007-03-19 Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG

2007-10-04 Publication of AU2007229554A1 publication Critical patent/AU2007229554A1/en

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 100
238000009472 formulation Methods 0.000 title claims description 77
241000282414 Homo sapiens Species 0.000 title claims description 33
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 95
229960002885 histidine Drugs 0.000 claims description 49
229920001213 Polysorbate 20 Polymers 0.000 claims description 45
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 45
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 45
229940068977 polysorbate 20 Drugs 0.000 claims description 41
108091006629 SLC13A2 Proteins 0.000 claims description 26
DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims description 24
229940074409 trehalose dihydrate Drugs 0.000 claims description 24
239000000872 buffer Substances 0.000 claims description 17
235000000346 sugar Nutrition 0.000 claims description 14
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
239000007788 liquid Substances 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 10
150000008163 sugars Chemical class 0.000 claims description 10
239000004094 surface-active agent Substances 0.000 claims description 10
229920000858 Cyclodextrin Polymers 0.000 claims description 9
150000001413 amino acids Chemical class 0.000 claims description 9
229940024606 amino acid Drugs 0.000 claims description 8
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 7
235000002639 sodium chloride Nutrition 0.000 claims description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
101150099875 atpE gene Proteins 0.000 claims description 6
101150018639 atpFH gene Proteins 0.000 claims description 6
101150048329 atpH gene Proteins 0.000 claims description 6
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
239000008103 glucose Substances 0.000 claims description 6
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 5
235000011187 glycerol Nutrition 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
229930006000 Sucrose Natural products 0.000 claims description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
239000003963 antioxidant agent Substances 0.000 claims description 4
235000006708 antioxidants Nutrition 0.000 claims description 4
239000004615 ingredient Substances 0.000 claims description 4
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
238000007920 subcutaneous administration Methods 0.000 claims description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
229960004793 sucrose Drugs 0.000 claims description 4
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 claims description 3
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 3
CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
229930091371 Fructose Natural products 0.000 claims description 3
239000005715 Fructose Substances 0.000 claims description 3
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 3
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
235000013681 dietary sucrose Nutrition 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
229930182830 galactose Natural products 0.000 claims description 3
229960002442 glucosamine Drugs 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 3
239000008101 lactose Substances 0.000 claims description 3
CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 claims description 3
239000001103 potassium chloride Substances 0.000 claims description 3
235000011164 potassium chloride Nutrition 0.000 claims description 3
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 3
239000011780 sodium chloride Substances 0.000 claims description 3
150000005846 sugar alcohols Polymers 0.000 claims description 3
-1 thimersal Chemical compound 0.000 claims description 3
229940074410 trehalose Drugs 0.000 claims description 3
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims description 2
241000283690 Bos taurus Species 0.000 claims description 2
206010006187 Breast cancer Diseases 0.000 claims description 2
208000026310 Breast neoplasm Diseases 0.000 claims description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
206010009944 Colon cancer Diseases 0.000 claims description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
229930195725 Mannitol Natural products 0.000 claims description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
206010060862 Prostate cancer Diseases 0.000 claims description 2
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
108010071390 Serum Albumin Proteins 0.000 claims description 2
102000007562 Serum Albumin Human genes 0.000 claims description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
159000000021 acetate salts Chemical class 0.000 claims description 2
239000011668 ascorbic acid Substances 0.000 claims description 2
235000010323 ascorbic acid Nutrition 0.000 claims description 2
229960005070 ascorbic acid Drugs 0.000 claims description 2
229960000686 benzalkonium chloride Drugs 0.000 claims description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
239000001110 calcium chloride Substances 0.000 claims description 2
235000011148 calcium chloride Nutrition 0.000 claims description 2
229960002713 calcium chloride Drugs 0.000 claims description 2
229910001628 calcium chloride Inorganic materials 0.000 claims description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 2
229960004926 chlorobutanol Drugs 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
235000019441 ethanol Nutrition 0.000 claims description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 2
235000003969 glutathione Nutrition 0.000 claims description 2
229960003180 glutathione Drugs 0.000 claims description 2
235000011147 magnesium chloride Nutrition 0.000 claims description 2
229960002337 magnesium chloride Drugs 0.000 claims description 2
229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
239000000594 mannitol Substances 0.000 claims description 2
235000010355 mannitol Nutrition 0.000 claims description 2
229960003194 meglumine Drugs 0.000 claims description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
229960002216 methylparaben Drugs 0.000 claims description 2
229960003742 phenol Drugs 0.000 claims description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
239000003755 preservative agent Substances 0.000 claims description 2
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
229960003415 propylparaben Drugs 0.000 claims description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
210000002966 serum Anatomy 0.000 claims description 2
235000017281 sodium acetate Nutrition 0.000 claims description 2
239000001632 sodium acetate Substances 0.000 claims description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
229960000281 trometamol Drugs 0.000 claims description 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 2
208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
102000009027 Albumins Human genes 0.000 claims 1
108010088751 Albumins Proteins 0.000 claims 1
208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
229960004249 sodium acetate Drugs 0.000 claims 1
230000027455 binding Effects 0.000 description 37
108010031794 IGF Type 1 Receptor Proteins 0.000 description 31
102000038455 IGF Type 1 Receptor Human genes 0.000 description 31
235000018102 proteins Nutrition 0.000 description 21
102000004169 proteins and genes Human genes 0.000 description 21
108090000623 proteins and genes Proteins 0.000 description 21
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 19
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 19
239000012669 liquid formulation Substances 0.000 description 17
241000894007 species Species 0.000 description 15
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 11
238000000034 method Methods 0.000 description 11
239000000243 solution Substances 0.000 description 11
239000000427 antigen Substances 0.000 description 10
108091007433 antigens Proteins 0.000 description 10
102000036639 antigens Human genes 0.000 description 10
206010028980 Neoplasm Diseases 0.000 description 8
235000001014 amino acid Nutrition 0.000 description 7
210000004602 germ cell Anatomy 0.000 description 7
238000003556 assay Methods 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
108060003951 Immunoglobulin Proteins 0.000 description 5
108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
238000004108 freeze drying Methods 0.000 description 5
102000018358 immunoglobulin Human genes 0.000 description 5
239000012931 lyophilized formulation Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
241001529936 Murinae Species 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
239000012894 fetal calf serum Substances 0.000 description 4
239000013628 high molecular weight specie Substances 0.000 description 4
239000012906 subvisible particle Substances 0.000 description 4
239000012905 visible particle Substances 0.000 description 4
108010047041 Complementarity Determining Regions Proteins 0.000 description 3
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 3
102100037852 Insulin-like growth factor I Human genes 0.000 description 3
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
229940126534 drug product Drugs 0.000 description 3
238000001035 drying Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
238000012538 light obscuration Methods 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
238000003860 storage Methods 0.000 description 3
238000010257 thawing Methods 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
229920002307 Dextran Polymers 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
108700005091 Immunoglobulin Genes Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
239000004809 Teflon Substances 0.000 description 2
229920006362 Teflon® Polymers 0.000 description 2
108700019146 Transgenes Proteins 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000012636 effector Substances 0.000 description 2
238000007710 freezing Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
235000001727 glucose Nutrition 0.000 description 2
230000036541 health Effects 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000012792 lyophilization process Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000008180 pharmaceutical surfactant Substances 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000003566 phosphorylation assay Methods 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000005180 public health Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
238000001542 size-exclusion chromatography Methods 0.000 description 2
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
238000000870 ultraviolet spectroscopy Methods 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
BGMYHTUCJVZIRP-SVZMEOIVSA-N (3r,4s,5s,6r)-6-(hydroxymethyl)piperidine-2,3,4,5-tetrol Chemical compound OC[C@H]1NC(O)[C@H](O)[C@@H](O)[C@H]1O BGMYHTUCJVZIRP-SVZMEOIVSA-N 0.000 description 1
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
108010031792 IGF Type 2 Receptor Proteins 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical class [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
102000004584 Somatomedin Receptors Human genes 0.000 description 1
108010017622 Somatomedin Receptors Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
239000006035 Tryptophane Substances 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960005261 aspartic acid Drugs 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
229940013361 cresol Drugs 0.000 description 1
238000009295 crossflow filtration Methods 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
230000003831 deregulation Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
238000012637 gene transfection Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
230000006698 induction Effects 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
230000006548 oncogenic transformation Effects 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
238000011085 pressure filtration Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
239000008362 succinate buffer Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

AU2007229554A 2006-03-28 2007-03-19 Anti-IGF-1R human monoclonal antibody formulation Abandoned AU2007229554A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP06111848		2006-03-28
EP06111848.5		2006-03-28
PCT/EP2007/052569 WO2007110339A1 (fr)	2006-03-28	2007-03-19	Formulation d'anticorps monoclonal humain anti-igf-1r

Publications (1)

Publication Number	Publication Date
AU2007229554A1 true AU2007229554A1 (en)	2007-10-04

Family

ID=37025222

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2007229554A Abandoned AU2007229554A1 (en)	2006-03-28	2007-03-19	Anti-IGF-1R human monoclonal antibody formulation

Country Status (18)

Country	Link
EP (1)	EP1998806A1 (fr)
JP (1)	JP2009531371A (fr)
KR (1)	KR20080104160A (fr)
CN (1)	CN101410137A (fr)
AR (1)	AR060130A1 (fr)
AU (1)	AU2007229554A1 (fr)
BR (1)	BRPI0709229A2 (fr)
CA (1)	CA2647111A1 (fr)
CL (1)	CL2007000797A1 (fr)
CR (1)	CR10295A (fr)
EC (1)	ECSP088778A (fr)
IL (1)	IL193904A0 (fr)
MA (1)	MA30345B1 (fr)
MX (1)	MX2008012295A (fr)
NO (1)	NO20083895L (fr)
RU (1)	RU2008142359A (fr)
TW (1)	TW200815029A (fr)
WO (1)	WO2007110339A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007331712A1 (en) *	2006-12-11	2008-06-19	F. Hoffmann-La Roche Ag	Abeta antibody parenteral formulation
GB0702888D0 (en) *	2007-02-14	2007-03-28	Glaxo Group Ltd	Novel Antibodies
BRPI0809112A2 (pt) *	2007-03-22	2014-08-26	Imclone Llc	Formulações estáveis de anticorpos
WO2009007272A1 (fr) *	2007-07-10	2009-01-15	F. Hoffmann-La Roche Ag	Nouvelle formulation
JP5205470B2 (ja) *	2007-11-29	2013-06-05	エフ．ホフマン−ラロシュアーゲー	免疫グロブリン凝集物
AU2008340429C1 (en) *	2007-12-21	2016-09-08	F. Hoffmann-La Roche Ag	Antibody formulation
WO2010069858A1 (fr) *	2008-12-19	2010-06-24	F. Hoffmann-La Roche Ag	Composition pharmaceutique
WO2010146059A2 (fr)	2009-06-16	2010-12-23	F. Hoffmann-La Roche Ag	Biomarqueurs pour une thérapie par inhibiteur d'igf-1r
US9345661B2 (en)	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CA2783715A1 (fr) *	2009-12-29	2011-07-07	F. Hoffmann-La Roche Ag	Nouvelle formation d'anticorps
US20130136733A1 (en) *	2010-05-28	2013-05-30	Novo Nordisk A/S	Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
AU2012236479B2 (en)	2011-03-31	2016-10-20	Merck Sharp & Dohme Llc	Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
CN102363040B (zh) *	2011-10-21	2013-05-01	北京锐瑟科技有限公司	用于粘膜组织的抗微生物肽制剂
JP2016528167A (ja)	2013-04-29	2016-09-15	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ヒトＦｃＲｎ結合改変抗体及び使用方法
CN105164157B (zh)	2013-04-29	2024-05-28	豪夫迈·罗氏有限公司	Fc-受体结合的修饰的非对称抗体及使用方法
CN103505729B (zh) *	2013-05-24	2015-10-28	华北制药集团新药研究开发有限责任公司	一种稳定的狂犬病毒人源抗体组合制剂
CN104707146B (zh) *	2013-12-16	2019-04-16	浙江海正药业股份有限公司	一种含有阿达木单抗的药物组合物
WO2015107015A1 (fr)	2014-01-15	2015-07-23	F. Hoffmann-La Roche Ag	Variants de région fc présentant une liaison améliorée à la protéine a
CA2950392A1 (fr) *	2014-05-28	2015-12-03	Nono Inc.	Formulation lyophilisee de tat-nr2b9c avec capteur d'acetylation
TW201628649A (zh) *	2014-10-09	2016-08-16	再生元醫藥公司	減少醫藥調配物中微可見顆粒之方法
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
UA123053C2 (uk)	2015-06-24	2021-02-10	Ф. Хоффманн-Ля Рош Аг	Антитіло до рецептора трансферину зі спеціально підібраною афінністю
JP6921062B2 (ja) *	2015-09-28	2021-08-18	スーヂョウサンケイディアバイオファーマスーティカルズカンパニーリミテッド	安定な抗ｐｄ−１抗体医薬製剤および医薬におけるその適用
MA43023A (fr)	2015-10-02	2018-08-08	Hoffmann La Roche	Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN106199007B (zh) *	2016-08-03	2017-04-05	烟台普罗吉生物科技发展有限公司	蛋白保护剂
US11020686B2 (en)	2016-08-16	2021-06-01	Regeneron Pharmaceuticals, Inc.	Methods for quantitating individual antibodies from a mixture
BR112019006689A2 (pt)	2016-10-25	2019-06-25	Regeneron Pharma	métodos e sistemas para análise de dados de cromatografia
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en)	2017-05-02	2023-12-19	Merck Sharp & Dohme Llc	Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
US12042538B2 (en)	2017-09-19	2024-07-23	Regeneron Pharmaceuticals, Inc.	Methods of reducing particle formation and compositions formed thereby
TWI853823B (zh)	2018-07-02	2024-09-01	美商里珍納龍藥品有限公司	自混合物製備多肽之系統及方法
KR20210089215A (ko)	2018-11-07	2021-07-15	머크 샤프 앤드 돔 코포레이션	항-lag3 항체 및 항-pd-1 항체의 공동-제제
CN114324882B (zh) *	2020-10-12	2022-12-27	广东菲鹏生物有限公司	蛋白稳定剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0999853B1 (fr) *	1997-06-13	2003-01-02	Genentech, Inc.	Formulation stabilisee renfermant un anticorps
MA26040A1 (fr) *	2001-01-05	2004-04-01	Pfizer	Des anticorps pour recepteur i de facteur de croissance insulinique
JP4317010B2 (ja) *	2001-07-25	2009-08-19	ピーディーエルバイオファーマ，インコーポレイティド	ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US7378503B2 (en) *	2003-04-02	2008-05-27	Hoffmann-La Roche Inc.	Antibodies against insulin-like growth factor 1 receptor and uses thereof
HRP20050934B1 (hr) *	2003-04-04	2014-09-26	Genentech, Inc.	Formulacije s visokom koncentracijom antitijela i proteina
AR046071A1 (es) *	2003-07-10	2005-11-23	Hoffmann La Roche	Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
JP4638870B2 (ja) *	2003-08-13	2011-02-23	ファイザー・プロダクツ・インク	修飾ヒトｉｇｆ−１ｒ抗体

2007
- 2007-03-19 JP JP2009502016A patent/JP2009531371A/ja active Pending
- 2007-03-19 KR KR1020087023673A patent/KR20080104160A/ko not_active Ceased
- 2007-03-19 EP EP07727047A patent/EP1998806A1/fr not_active Withdrawn
- 2007-03-19 CN CNA2007800114320A patent/CN101410137A/zh active Pending
- 2007-03-19 RU RU2008142359/15A patent/RU2008142359A/ru not_active Application Discontinuation
- 2007-03-19 CA CA002647111A patent/CA2647111A1/fr not_active Abandoned
- 2007-03-19 BR BRPI0709229-6A patent/BRPI0709229A2/pt not_active IP Right Cessation
- 2007-03-19 AU AU2007229554A patent/AU2007229554A1/en not_active Abandoned
- 2007-03-19 MX MX2008012295A patent/MX2008012295A/es active IP Right Grant
- 2007-03-19 WO PCT/EP2007/052569 patent/WO2007110339A1/fr not_active Ceased
- 2007-03-26 CL CL2007000797A patent/CL2007000797A1/es unknown
- 2007-03-26 TW TW096110388A patent/TW200815029A/zh unknown
- 2007-03-26 AR ARP070101241A patent/AR060130A1/es not_active Application Discontinuation
2008
- 2008-09-04 IL IL193904A patent/IL193904A0/en unknown
- 2008-09-11 NO NO20083895A patent/NO20083895L/no not_active Application Discontinuation
- 2008-09-17 CR CR10295A patent/CR10295A/es not_active Application Discontinuation
- 2008-09-26 EC EC2008008778A patent/ECSP088778A/es unknown
- 2008-10-20 MA MA31308A patent/MA30345B1/fr unknown

Also Published As

Publication number	Publication date
CL2007000797A1 (es)	2008-01-25
CA2647111A1 (fr)	2007-10-04
TW200815029A (en)	2008-04-01
NO20083895L (no)	2008-10-24
MX2008012295A (es)	2008-10-09
MA30345B1 (fr)	2009-04-01
CR10295A (es)	2008-10-06
IL193904A0 (en)	2011-08-01
KR20080104160A (ko)	2008-12-01
WO2007110339A1 (fr)	2007-10-04
JP2009531371A (ja)	2009-09-03
RU2008142359A (ru)	2010-05-10
AR060130A1 (es)	2008-05-28
ECSP088778A (es)	2008-10-31
EP1998806A1 (fr)	2008-12-10
BRPI0709229A2 (pt)	2011-06-28
CN101410137A (zh)	2009-04-15

Publication	Publication Date	Title
AU2007229554A1 (en)	2007-10-04	Anti-IGF-1R human monoclonal antibody formulation
US20240058263A1 (en)	2024-02-22	Formulations of antibody
US20100158919A1 (en)	2010-06-24	Pharmaceutical Composition
TWI761869B (zh)	2022-04-21	包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途
US20100158925A1 (en)	2010-06-24	Lyophilized formulations of anti-egfr antibodies
US20100260766A1 (en)	2010-10-14	Stable antibody formulations
KR20180100439A (ko)	2018-09-10	이중특이적 항체 작제물을 포함하는 약제학적 조성물
JP7475335B2 (ja)	2024-04-26	Ｃｓｆ－１ｒ抗体製剤
TW201420601A (zh)	2014-06-01	抗ｔｓｌｐ抗體之安定調配物
PL205982B1 (pl)	2010-06-30	Liofilizowany preparat zawierający przeciwciała przeciw receptorowi EGF oraz sposób jego otrzymywania
CN113194925B (zh)	2025-03-07	抗体制剂
KR20230058432A (ko)	2023-05-03	약제학적 제형
HK1130669A (zh)	2010-01-08	抗-igf-1r人单克隆抗体制剂
KR20220044286A (ko)	2022-04-07	항 pd-1/her2 이중특이성 항체를 포함하는 제제, 이의 제조 방법 및 용도
CN114832102A (zh)	2022-08-02	一种稳定的抗egfr抗体组合物
HK40052133A (en)	2022-01-14	Csf-1r antibody formulation
HK1247124B (zh)	2022-03-18	抗表皮生长因子受体单克隆抗体的注射液制剂

Legal Events

Date	Code	Title	Description
2011-09-29	MK3	Application lapsed section 142(2)(c) - examination deferred under section 46 no request for examination